Post-licensure safety surveillance of 9-valent human papillomavirus vaccine using the vaccine adverse event reporting system, 2014–2024
Frontiers in Public Health · 2026
DOI: 10.3389/fpubh.2026.1724482 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Public Health, 2026. Verfasst von Jie-Hai Chen und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Anesthesiology, Dongguan Maternal and Child Health Care Hospital, Dongguan, Guangdong, China. Hauptthemen laut MEDLINE: Papillomavirus Vaccines, Adverse Drug Reaction Reporting Systems, Product Surveillance, Postmarketing, Papillomavirus Infections. Die Arbeit nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
On December 10, 2014, the Food and Drug Administration (FDA) licensed the 9-valent human papillomavirus vaccine (9vHPV) for prevention of HPV-related cancers and genital warts. This study aimed to summarize and characterize the first decade of post-licensure surveillance reports of 9vHPV submitted to the Vaccine Adverse Event Reporting System (VAERS).
Methods
We analyzed VAERS reports following 9vHPV administration in the U.S. during December 2014 through December 2024. Disproportionality analysis was conducted using the reporting odds ratio (ROR) to identify potential safety signals. Reports were categorized by sex, age, seriousness, and clinical outcomes.
Results
The VAERS received 23,499 reports following administration of 9vHPV: 46.7% were from females, 25.7% from males, and 27.6% with unreported sex. Overall, 92.5% of reports were nonserious. Syncope, dizziness, loss of consciousness and pallor were most common AEs among nonserious reports. Headache, dizziness, pain and syncope were commonly reported serious AEs. Disproportionality analysis identified six MedDRA PTs that were disproportionately reported following 9vHPV vaccination: anaphylactic shock, postural orthostatic tachycardia syndrome (POTS), dizziness postural, complex regional pain syndrome (CRPS), premature menopause and acute disseminated encephalomyelitis (ADEM). Deaths ( N = 57) were rare and most lacked sufficient medical documentation to establish causality.
Conclusion
The safety profile of 9vHPV over its first decade of use remains consistent with pre-licensure data, with most AEs being nonserious and self-limiting. Disproportionality analysis identified potential safety signals warranting further investigation but did not confirm causality. Continuous surveillance is necessary to further evaluate these rare events and ensure the ongoing safety of 9vHPV.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Anesthesiology, Dongguan Maternal and Child Health Care Hospital, Dongguan, Guangdong, China.
- Department of Gynecology, Dongguan Maternal and Child Health Care Hospital, Dongguan, Guangdong, China.
- Dongguan Maternal and Child Health Care Hospital, Dongguan, Guangdong, China.
Zitieren
APA
Chen, J. H., Chen, M., Wu, Z. Y., Luo, Q. M., & Tu, Y. Y. (2026). Post-licensure safety surveillance of 9-valent human papillomavirus vaccine using the vaccine adverse event reporting system, 2014–2024. Frontiers in Public Health. https://doi.org/10.3389/fpubh.2026.1724482
Vancouver
Chen JH, Chen M, Wu ZY, Luo QM, Tu YY. Post-licensure safety surveillance of 9-valent human papillomavirus vaccine using the vaccine adverse event reporting system, 2014–2024. Frontiers in Public Health. 2026. doi:10.3389/fpubh.2026.1724482
BibTeX
@article{Chen2026,
author = {Chen, Jie-Hai and Chen, Ming and Wu, Zhi-Yong and Luo, Qing-Ming and Tu, Yuan-Yan},
title = {Post-licensure safety surveillance of 9-valent human papillomavirus vaccine using the vaccine adverse event reporting system, 2014–2024},
journal = {Frontiers in Public Health},
year = {2026},
doi = {10.3389/fpubh.2026.1724482}
}
EUVIMED